|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Orr GA, Verdier-Pinard P, McDaid H and
Horwitz SB: Mechanisms of Taxol resistance related to microtubules.
Oncogene. 22:7280–7295. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Katsetos CD, Herman MM and Mörk SJ: Class
III beta-tubulin in human development and cancer. Cell Motil
Cytoskeleton. 55:77–96. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Leandro-García LJ, Leskelä S, Landa I,
Montero-Conde C, López-Jiménez E, Letón R, Cascón A, Robledo M and
Rodríguez-Antona C: Tumoral and tissue-specific expression of the
major human beta-tubulin isotypes. Cytoskeleton (Hoboken).
67:214–223. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tsourlakis MC, Weigand P, Grupp K, Kluth
M, Steurer S, Schlomm T, Graefen M, Huland H, Salomon G, Steuber T,
et al: βIII-tubulin overexpression is an independent predictor of
prostate cancer progression tightly linked to ERG fusion status and
PTEN deletion. Am J Pathol. 184:609–617. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ferrandina G, Zannoni GF, Martinelli E,
Paglia A, Gallotta V, Mozzetti S, Scambia G and Ferlini C: Class
III beta-tubulin overexpression is a marker of poor clinical
outcome in advanced ovarian cancer patients. Clin Cancer Res.
12:2774–2779. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hetland TE, Hellesylt E, Flørenes VA,
Tropé C, Davidson B and Kærn J: Class III β-tubulin expression in
advanced-stage serous ovarian carcinoma effusions is associated
with poor survival and primary chemoresistance. Hum Pathol.
42:1019–1026. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Koh Y, Jang B, Han SW, Kim TM, Oh DY, Lee
SH, Kang CH, Kim DW, Im SA, Chung DH, et al: Expression of class
III beta-tubulin correlates with unfavorable survival outcome in
patients with resected non-small cell lung cancer. J Thorac Oncol.
5:320–325. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang HL, Ruan L, Zheng LM, Whyte D, Tzeng
CM and Zhou XW: Association between class III β-tubulin expression
and response to paclitaxel/vinorebine-based chemotherapy for
non-small cell lung cancer: A meta-analysis. Lung Cancer. 77:9–15.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chen X, Wu J, Lu H, Huang O and Shen K:
Measuring β-tubulin III, Bcl-2, and ERCC1 improves pathological
complete remission predictive accuracy in breast cancer. Cancer
Sci. 103:262–268. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zheng WE, Chen H, Yuan SF, Wu LL, Zhang W,
Sun HY and Chen WJ: Overexpression of βIII-tubulin and survivin
associated with drug resistance to docetaxel-based chemotherapy in
advanced gastric cancer. J BUON. 17:284–290. 2012.PubMed/NCBI
|
|
12
|
Galmarini CM, Treilleux I, Cardoso F,
Bernard-Marty C, Durbecq V, Gancberg D, Bissery MC, Paesmans M,
Larsimont D, Piccart MJ, et al: Class III beta-tubulin isotype
predicts response in advanced breast cancer patients randomly
treated either with single-agent doxorubicin or docetaxel. Clin
Cancer Res. 14:4511–4516. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yuan SF, Zhu LJ, Zheng WE, Chen H, Wu LL,
Zhang W, Sun HY and Chen WJ: Expression of β-tubulin III and
survivin in advance stage breast cancer correlates with
chemotherapeutic effects of docetaxel. Asian Pac J Cancer Prev.
13:361–365. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jung M, Koo JS, Moon YW, Park BW, Kim SI,
Park S, Lee SH, Hong S, Rha SY, Chung HC, et al: Overexpression of
class III beta tubulin and amplified HER2 gene predict good
response to paclitaxel and trastuzumab therapy. PLoS One.
7:e451272012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang YI, Sparano JA, Fineberg S, Stead L,
Sunkara J, Horwitz SB and McDaid HM: High expression of class III
β-tubulin predicts good response to neoadjuvant taxane and
doxorubicin/cyclophosphamide-based chemotherapy in estrogen
receptor-negative breast cancer. Clin Breast Cancer. 13:103–108.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pentheroudakis G, Batistatou A, Kalogeras
KT, Kronenwett R, Wirtz RM, Bournakis E, Eleftheraki AG, Pectasides
D, Bobos M, Papaspirou I, et al: Prognostic utility of β-tubulin
isotype III and correlations with other molecular and
clinicopathological variables in patients with early breast cancer:
A translational Hellenic Cooperative Oncology Group (HeCOG) study.
Breast Cancer Res Treat. 127:179–193. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Horak CE, Pusztai L, Xing G, Trifan OC,
Saura C, Tseng LM, Chan S, Welcher R and Liu D: Biomarker analysis
of neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone
or Paclitaxel in early-stage breast cancer. Clin Cancer Res.
19:1587–1595. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Dumontet C, Krajewska M, Treilleux I,
Mackey JR, Martin M, Rupin M, Lafanechère L and Reed JC: BCIRG 001
molecular analysis: Prognostic factors in node-positive breast
cancer patients receiving adjuvant chemotherapy. Clin Cancer Res.
16:3988–3997. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ruiz C, Seibt S, Al Kuraya K, Siraj AK,
Mirlacher M, Schraml P, Maurer R, Spichtin H, Torhorst J, Popovska
S, et al: Tissue microarrays for comparing molecular features with
proliferation activity in breast cancer. Int J Cancer.
118:2190–2194. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Elston CW and Ellis IO: Pathological
prognostic factors in breast cancer I. The value of histological
grade in breast cancer: Experience from a large study with
long-term follow-up. Histopathology. 19:403–410. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Al-Kuraya K, Schraml P, Torhorst J, Tapia
C, Zaharieva B, Novotny H, Spichtin H, Maurer R, Mirlacher M,
Köchli O, et al: Prognostic relevance of gene amplifications and
coamplifications in breast cancer. Cancer Res. 64:8534–8540. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ploussard G, Terry S, Maillé P, Allory Y,
Sirab N, Kheuang L, Soyeux P, Nicolaiew N, Coppolani E, Paule B, et
al: Class III beta-tubulin expression predicts prostate tumor
aggressiveness and patient response to docetaxel-based
chemotherapy. Cancer Res. 70:9253–9264. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Minner S, Wittmer C, Graefen M, Salomon G,
Steuber T, Haese A, Huland H, Bokemeyer C, Yekebas E, Dierlamm J,
et al: High level PSMA expression is associated with early PSA
recurrence in surgically treated prostate cancer. Prostate.
71:281–288. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Choschzick M, Lebeau A, Marx AH, Tharun L,
Terracciano L, Heilenkötter U, Jaenicke F, Bokemeyer C, Simon R,
Sauter G and Schwarz J: Overexpression of cell division cycle 7
homolog is associated with gene amplification frequency in breast
cancer. Hum Pathol. 41:358–365. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Choschzick M, Lassen P, Lebeau A, Marx AH,
Terracciano L, Heilenkötter U, Jaenicke F, Bokemeyer C, Izbicki J,
Sauter G and Simon R: Amplification of 8q21 in breast cancer is
independent of MYC and associated with poor patient outcome. Mod
Pathol. 23:603–610. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Burandt E, Jens G, Holst F, Jänicke F,
Müller V, Quaas A, Choschzick M, Wilczak W, Terracciano L, Simon R,
et al: Prognostic relevance of AIB1 (NCoA3) amplification and
overexpression in breast cancer. Breast Cancer Res Treat.
137:745–753. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Stockinger A, Eger A, Wolf J, Beug H and
Foisner R: E-cadherin regulates cell growth by modulating
proliferation-dependent beta-catenin transcriptional activity. J
Cell Biol. 154:1185–1196. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
van Roy F and Berx G: The cell-cell
adhesion molecule E-cadherin. Cell Mol Life Sci. 65:3756–3788.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kitase Y and Shuler CF: Microtubule
disassembly prevents palatal fusion and alters regulation of the
E-cadherin/catenin complex. Int J Dev Biol. 57:55–60. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Levallet G, Bergot E, Antoine M, Creveuil
C, Santos AO, Beau-Faller M, de Fraipont F, Brambilla E, Levallet
J, Morin F, et al: High TUBB3 expression, an independent prognostic
marker in patients with early non-small cell lung cancer treated by
preoperative chemotherapy, is regulated by K-Ras signaling pathway.
Mol Cancer Ther. 11:1203–1213. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gao S, Zhao X, Lin B, Hu Z, Yan L and Gao
J: Clinical implications of REST and TUBB3 in ovarian cancer and
its relationship to paclitaxel resistance. Tumour Biol.
33:1759–1765. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Carrara L, Guzzo F, Roque DM, Bellone S,
Emiliano C, Sartori E, Pecorelli S, Schwartz PE, Rutherford TJ and
Santin AD: Differential in vitro sensitivity to patupilone
versus paclitaxel in uterine and ovarian carcinosarcoma cell lines
is linked to tubulin-beta-III expression. Gynecol Oncol.
125:231–236. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Katsetos CD, Legido A, Perentes E and Mörk
SJ: Class III beta-tubulin isotype: A key cytoskeletal protein at
the crossroads of developmental neurobiology and tumor
neuropathology. J Child Neurol. 18:851–867. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Panda D, Miller HP, Banerjee A, Ludueña RF
and Wilson L: Microtubule dynamics in vitro are regulated by
the tubulin isotype composition. Proc Natl Acad Sci USA.
91:11358–11362. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Falconer MM, Echeverri CJ and Brown DL:
Differential sorting of beta tubulin isotypes into
colchicine-stable microtubules during neuronal and muscle
differentiation of embryonal carcinoma cells. Cell Motil
Cytoskeleton. 21:313–325. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sève P and Dumontet C: Is class III
beta-tubulin a predictive factor in patients receiving
tubulin-binding agents? Lancet Oncol. 9:168–175. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Jordan MA, Toso RJ, Thrower D and Wilson
L: Mechanism of mitotic block and inhibition of cell proliferation
by taxol at low concentrations. Proc Natl Acad Sci USA.
90:9552–9556. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Dumontet C and Sikic BI: Mechanisms of
action of and resistance to antitubulin agents: Microtubule
dynamics, drug transport, and cell death. J Clin Oncol.
17:1061–1070. 1999.PubMed/NCBI
|
|
39
|
Narvi E, Jaakkola K, Winsel S,
Oetken-Lindholm C, Halonen P, Kallio L and Kallio MJ: Altered TUBB3
expression contributes to the epothilone response of mitotic cells.
Br J Cancer. 108:82–90. 2013. View Article : Google Scholar : PubMed/NCBI
|
